TACSTD2 and Familial prostate cancer: In this study, we present data that provide some preclinical evidence of the oncogenic role of dysregulated GSE1-TACSTD2 signaling, and show that the molecular or pharmacological targeting of GSE1 is a workable treatment strategy for inhibiting androgen-driven oncogenic signals, re-sensitizing cancerous cells to treatment, and repressing the metastatic-recurrent phenotypes of patients with prostate cancer.